Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-12-08
2010-10-05
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C514S017400, C514S199000, C514S256000, C514S338000, C514S361000, C530S300000, C530S326000, C530S330000, C424S009100
Reexamination Certificate
active
07807623
ABSTRACT:
This invention pertains to the discovery administration of a CCK receptor agonist can increase urinary sodium excretion and/or free water excretion in a mammal. CCK receptor agonist can thereby be used in the treatment of conditions such high blood pressure, fluid retention associated with heart failure, fluid retention associated with acute or chronic kidney failure, fluid retention associated with cirrhosis, fluid retention associated with liver failure, calcium kidney stones, nephrogenic diabetes insipidus, and renal tubular acidosis.
REFERENCES:
patent: 4997950 (1991-03-01), Murphy et al.
patent: 5629305 (1997-05-01), Eek et al.
patent: 5750531 (1998-05-01), Lee et al.
patent: 5877192 (1999-03-01), Lindberg et al.
patent: 6013281 (2000-01-01), Lundberg et al.
patent: 6093738 (2000-07-01), Karimian et al.
patent: 7365047 (2008-04-01), Pisegna
patent: 2008/0045462 (2008-02-01), Pisegna et al.
patent: WO 01/22985 (2001-04-01), None
Calam et al., Br. J. Pharmac. 91, 307-314 (1987).
International Search Report dated Aug. 29, 2001 from PCT/US/00/26992.
Office Action dated Nov. 27, 2002 in U.S. Appl. No. 09/671,764.
Office Action dated Aug. 18, 2003 in U.S. Appl. No. 09/671,764.
Office Action dated May 12, 2004 in U.S. Appl. No. 09/671,764.
Office Action dated Feb. 8, 2005 in U.S. Appl. No. 09/671,764.
Office Action dated Feb. 2, 2006 in U.S. Appl. No. 09/671,764.
Office Action dated Oct. 26, 2006 in U.S. Appl. No. 09/671,764.
Office Action dated Jun. 28, 2007 in U.S. Appl. No. 09/671,764.
Bonfils et al., Cimetidine Treatment of Acute and Chronic Zollinger-Ellison Syndrome, 1979World J. Surg. 3: 597-604.
Campoli-Richards et al. Famotidine Pharmacodynamic and Pharmacokinetic properties and a Preliminary Reivew of its Therapeutic Use . . . 1986 Drugs 32: 197-221.
Chin et al. Absence of Tachyphylasix in Gastric Acid Secretion . . . 1986J. Clin. Pharm. 26: 281-285.
Davidson et al. Renal Extraction and Excretion of Endogenous Gastric in the Dog, 1973Gastroenterology64: 955-961.
De Graef and Woussen-Cole, Influence of the Stimulation o State of the Parietal Cells on the Inhibitory Effect . . . 1986,Gastroenterology9: 333-337.
Desanto et al., Brain-Gut Peptides and the Renal Hemodynamic Response . . . 1992Renal Physiol. Biochem.. 15: 53-56.
Deveney et al. Cimetidine in the Treatment of Zollinger-Ellison Syndrome, 1983,Amer. J. Surg. 146: 116-123.
Brogden et al., 1978,Drugs15: 93-131.
El Munshid et al, 1980,J.Physiol., 299: 157-171.
Fraker et al., A Prospective Study of Perioperative and Postoperative Control of Acid Hypersecretion in Patients with Zollinger-Ellizon Syundrome Undergoing Gastrinoma Resection, 1988,Surgery, 104: 6: 1054-1063.
Hansky, Effect of Renal Failure on gastrointestinal Hormones, 1979,World J. Surg. 3:463-467.
Hartman et al. Equipotent Inhibition of Gastric Acid secretion by Equal Doses of Oral . . . 1998Aliment. Pharmacol. Ther. 12: 1027-1032.
Hirschowitz et al., Pharmacological Aspects of Acid Secretion. 1995Dig. Dis. Sci. 40: 2 (suppl) 3S-23S.
Hostetter, Human Renal Reponse to a Meat Meal, 1986Am J. Physiol. 1986, 250:F613-618.
Howard et al., Famotidine, a New Potent, Long-Acting Histamine . . . (1985),Gastroenterology88: 1026-1033.
Kes et al., Influence of Renal functional Mass on the Catabolism of Endogenous Gastrine in Humans, 1993,Renal Physiol. Biochem. 16: 268-275.
Kromer et al., Animal Pharmacology of Reversible Antagonism of the Gastric Acid Pump . . . , 2000,Pharmacology60: 179-187.
Lotti and Change, A New Potent and Selective Non-Peptide Gastrin Antagonist . . . 1989,Eur. J. Pharmacol. 162: 273-280.
Mason et al. Continuous Intravenous Pentagastrin as a Stimulant of Maximal Gastric Acid Secretion, 1969Gut., 10: 34-38.
McCarthy, Report on the United States Experience with Cimetidine in Zollinger-Ellison Syndrome and Other Hypertsecretory States, 1978,Gastroenterology74: 453-458.
Nielsen et al., The Effect of Renal Transplantation on Basal Serum Gastrin Concentration., 1980Acta. Med. Scand. 207: 85-87.
Richardson et al., Proton Pump Inhibitors: Pharmacology and Rationale for use in Gastrointestinal Disorders, 1998,Drugs56 (3) 307-335.
Rune et al., Abstracts of Papers, 1981,Gastroenterology80: 1265.
Saeed et al., Parenteral Antisecretory Drug Therapy in Patients with Zollinger-Ellison Syndrome, 1989,Gastroenterology96: 1393-1402.
Schjonsby and Willassen, Renal Extraction of Endogenous Gastrin in Patients with Normal Renal Function, 1977,Gastroenterology12: 205-207.
Simon et al., Pentagastrin-Stimulated Gastric Acid Secretion and Pharmacokinetics . . . 1990,Gastroenterology18:443-447.
Simon et al., Single Intravenous Administration of the H+, K+-ATPase Inhibitor . . . 1990,Aliment Pharmacol. Therap. 4: 239-245.
Vallot et al., Evaluation of Antisecretory Drug Theraphy of Zollinger-Ellison Syndrome . . . , 1983,Dig. Dis. Sci. 28: 7:577-584.
Wank et al., Brain and Gastrointestinal Cholecystokinin Receptor Family . . . 1, 1992,Proc. Natl. Acad. Sci., USA, 89: 8691-8695.
Wormsley et al., Effects of a Gastrin0Line Pentapeptide (I.C.I.50, 123) on Stomach and Pancreas, 1966,Lancet, 1: 993-996.
US Notice of Allowance dated Dec. 6, 2007 issued in U.S. Appl. No. 09/671,764 (7,365,047).
US Office Action dated Apr. 17, 2008 issued in U.S. Appl. No. 11/830,651.
US Office Action dated Dec. 31, 2008 issued in U.S. Appl. No. 11/830,651.
PCT International Preliminary Examination Report dated Aug. 29, 2001 issued in PCT/US00/26992 (WO 2001/022985).
PCT International Search Report dated Jan. 22, 2001 issued in PCT/US00/26992 (WO 2001/022985).
Pisegna Joseph R.
Wank Stephen
Kam Chih-Min
The Regents of the University of California
Weaver Austin Villeneuve & Sampson LLP
LandOfFree
Use of pentagastrin to inhibit gastric acid secretion or as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of pentagastrin to inhibit gastric acid secretion or as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of pentagastrin to inhibit gastric acid secretion or as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4210384